# Shenzhen Chipscreen Biosciences Wins Approval for NW001 Phase 1 Cancer Trial

- URL: https://stocks.freetheai.org/news/shenzhen-chipscreen-biosciences-wins-approval-for-nw001-phase-1-cancer-trial-9c2896
- Published: 2026-10-16T13:30:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [SSE:688321](https://stocks.freetheai.org/symbols/SSE-688321)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Chinese health regulators have granted Investigational New Drug clearance to Shenzhen Chipscreen Biosciences Co., Ltd. (SSE:688321) to begin a Phase 1 clinical trial for NW001. The early-stage trial will evaluate the experimental treatment in China among patients diagnosed with advanced tumors. Shares of the company last traded down 0.59% at 21.8 CNY.

The drug candidate, NW001, is an antibody conjugate designed to target PD-L1 with an HDACi payload. It aims to reduce systemic exposure and expand therapeutic potential to tumors that do not respond to existing PD-1 or PD-L1 therapies. The trial approval marks a key step in broadening the company's immuno-oncology portfolio beyond its approved drug, chidamide.

Investors and researchers will monitor the Phase 1 and subsequent Phase 1b trials for initial safety data and early signs of antitumor effectiveness. Demonstrating a favorable safety profile and clinical activity will be crucial for the company to attract future partnerships, secure funding, or support pipeline valuation.

## Key points

- Shenzhen Chipscreen Biosciences received IND approval in China for a Phase 1 trial of NW001 in advanced tumors.
- NW001 combines a PD-L1-targeting antibody with an HDACi payload to improve tolerability and target resistant tumors.
- The milestone expands the company's immuno-oncology pipeline beyond its approved drug chidamide.
- Future clinical progress will focus on establishing safety and preliminary antitumor activity in early testing.

## Questions and answers

### What is NW001 developed by Shenzhen Chipscreen Biosciences?

NW001 is a PD-L1-targeted antibody conjugate with an HDACi payload designed to treat advanced tumors while lowering systemic exposure.

### What approval did Shenzhen Chipscreen Biosciences receive for NW001?

The company received Investigational New Drug approval in China to launch a Phase 1 clinical trial in patients with advanced tumors.

### What is the next step for NW001's development?

Researchers will evaluate the safety profile and preliminary antitumor activity of NW001 during Phase 1 and Phase 1b clinical trials.